These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 31201151)
21. Insights on efficacious doses of PAMORAs for patients on chronic opioid therapy or opioid-naïve patients. van Malderen K; Halawi H; Camilleri M Neurogastroenterol Motil; 2018 May; 30(5):e13250. PubMed ID: 29119706 [TBL] [Abstract][Full Text] [Related]
22. Cost Effectiveness of Naloxegol for Opioid-Induced Constipation in the UK. Lawson R; Ryan J; King F; Goh JW; Tichy E; Marsh K Pharmacoeconomics; 2017 Feb; 35(2):225-235. PubMed ID: 27663572 [TBL] [Abstract][Full Text] [Related]
23. Naloxegol: the first orally administered, peripherally acting, mu opioid receptor antagonist, approved for the treatment of opioid-induced constipation. Corsetti M; Tack J Drugs Today (Barc); 2015 Aug; 51(8):479-89. PubMed ID: 26380386 [TBL] [Abstract][Full Text] [Related]
24. Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients' Health State Utility. Lawson R; King F; Marsh K; Altincatal A; Cimen A Adv Ther; 2016 Aug; 33(8):1331-46. PubMed ID: 27342744 [TBL] [Abstract][Full Text] [Related]
25. Naloxegol increases frequency of bowel movements and combats inadequate response to laxatives. Holzer P Evid Based Med; 2015 Feb; 20(1):5. PubMed ID: 25209526 [No Abstract] [Full Text] [Related]
26. Pharmacological characterization of naloxegol: In vitro and in vivo studies. Costanzini A; Ruzza C; Neto JA; Sturaro C; Malfacini D; Sternini C; De Giorgio R; Calò G Eur J Pharmacol; 2021 Jul; 903():174132. PubMed ID: 33933466 [TBL] [Abstract][Full Text] [Related]
27. Population Exposure-Response Modeling of Naloxegol in Patients With Noncancer-Related Pain and Opioid-Induced Constipation. Al-Huniti N; Nielsen JC; Hutmacher MM; Lappalainen J; Cantagallo K; Sostek M CPT Pharmacometrics Syst Pharmacol; 2016 Jul; 5(7):359-66. PubMed ID: 27435972 [TBL] [Abstract][Full Text] [Related]
28. Pharmacometric Modeling of Naloxegol Efficacy and Safety: Impact on Dose and Label. Al-Huniti N; Zhou D; Xu H; Aksenov S; Bui KH; Fox R; Helmlinger G; Stanski D Clin Pharmacol Ther; 2017 Nov; 102(5):741-744. PubMed ID: 28548207 [TBL] [Abstract][Full Text] [Related]
29. Naloxegol oxalate, pirfenidone, and nintedanib. Hussar DA; Jeon MM J Am Pharm Assoc (2003); 2015; 55(4):461-3. PubMed ID: 26161491 [No Abstract] [Full Text] [Related]
30. Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of naloxegol at peripheral and central nervous system receptors in healthy male subjects: A single ascending-dose study. Eldon MA; Kugler AR; Medve RA; Bui K; Butler K; Sostek M Clin Pharmacol Drug Dev; 2015 Nov; 4(6):434-41. PubMed ID: 27137715 [TBL] [Abstract][Full Text] [Related]
31. Naloxegol: treatment for opioid-induced constipation in chronic non-cancer pain. Leonard J; Baker DE Ann Pharmacother; 2015 Mar; 49(3):360-5. PubMed ID: 25471070 [TBL] [Abstract][Full Text] [Related]
32. Naloxegol: A Review of Clinical Trials and Applications to Practice. Dume R; Shuman M Orthop Nurs; 2019; 38(3):209-211. PubMed ID: 31124873 [TBL] [Abstract][Full Text] [Related]
33. Periarticular Morphine-Induced Sphincter of Oddi Spasm Causing Severe Pain and Bradycardia in an Awake Patient Under Spinal Anesthesia: An Important Diagnostic Consideration. Koumpan Y; Engen D; Tanzola R; Saha T A A Case Rep; 2016 Oct; 7(7):152-4. PubMed ID: 27513967 [TBL] [Abstract][Full Text] [Related]
34. Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine-morphine administration. Velosy B; Madácsy L; Lonovics J; Csernay L Eur J Gastroenterol Hepatol; 1997 Nov; 9(11):1109-12. PubMed ID: 9431903 [TBL] [Abstract][Full Text] [Related]
35. Challenges in Recruiting Patients to a Controlled Feasibility Study of a Drug for Opioid-Induced Constipation: Lessons From the Population With Advanced Cancer. Bull J; Bonsignore L; Massie L; Riggs A; Knotkova H; Wellman C; Portenoy R J Pain Symptom Manage; 2019 May; 57(5):e5-e8. PubMed ID: 30853551 [No Abstract] [Full Text] [Related]
36. Cholangiographic demonstration of relief of narcotic-induced spasm of the sphincter of Oddi. McLean ER; Widmann WD; Small HS Am Surg; 1982 Mar; 48(3):134-6. PubMed ID: 7073136 [TBL] [Abstract][Full Text] [Related]